This article was originally published in The Gray Sheet
Research partnership with the Novartis Institute for Functional Genomics is announced Dec. 17. The agreement allows Novartis access to Invitrogen's cloning and expression kits in exchange for commercial rights to any genes discovered by NIFG using the technology (1see related story, p. 19)
You may also be interested in...
Invitrogen's acquisition of Research Genetics in a stock transaction valued at $158 mil. will allow the company's expanded sales force to offer products and services in four key areas of the genomic discovery cycle.
As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.
The IVDR implementation schedule is problematic. European notified bodies say solutions must be grasped if public health is not to suffer.